T. Rowe Price Associates’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $786M | Sell |
1,760,122
-518,836
| -23% | -$242M | 0.09% | 182 |
|
|
2025
Q4 | $1.03B | Sell |
2,278,958
-764,847
| -25% | -$330M | 0.11% | 154 |
|
|
2025
Q3 | $1.19B | Sell |
3,043,805
-116,065
| -4% | -$48.5M | 0.13% | 139 |
|
|
2025
Q2 | $1.41B | Buy |
3,159,870
+242,643
| +8% | +$112M | 0.16% | 124 |
|
|
2025
Q1 | $1.41B | Buy |
2,917,227
+1,226,527
| +73% | +$572M | 0.17% | 116 |
|
|
2024
Q4 | $681M | Sell |
1,690,700
-77,310
| -4% | -$35.8M | 0.08% | 222 |
|
|
2024
Q3 | $822M | Sell |
1,768,010
-443,664
| -20% | -$213M | 0.09% | 193 |
|
|
2024
Q2 | $1.04B | Sell |
2,211,674
-2,281,748
| -51% | -$990M | 0.12% | 156 |
|
|
2024
Q1 | $1.88B | Sell |
4,493,422
-1,393,990
| -24% | -$589M | 0.23% | 88 |
|
|
2023
Q4 | $2.4B | Sell |
5,887,412
-962,654
| -14% | -$356M | 0.32% | 61 |
|
|
2023
Q3 | $2.38B | Buy |
6,850,066
+91,308
| +1% | +$31.9M | 0.35% | 54 |
|
|
2023
Q2 | $2.38B | Buy |
6,758,758
+168,568
| +3% | +$56.8M | 0.33% | 54 |
|
|
2023
Q1 | $2.08B | Buy |
6,590,190
+1,892,523
| +40% | +$568M | 0.31% | 66 |
|
|
2022
Q4 | $1.36B | Sell |
4,697,667
-460,287
| -9% | -$140M | 0.22% | 99 |
|
|
2022
Q3 | $1.49B | Buy |
5,157,954
+195,271
| +4% | +$56.2M | 0.24% | 81 |
|
|
2022
Q2 | $1.4B | Sell |
4,962,683
-342,014
| -6% | -$91.5M | 0.18% | 121 |
|
|
2022
Q1 | $1.38B | Sell |
5,304,697
-116,594
| -2% | -$27.7M | 0.14% | 151 |
|
|
2021
Q4 | $1.19B | Sell |
5,421,291
-276,956
| -5% | -$53.9M | 0.11% | 185 |
|
|
2021
Q3 | $1.03B | Sell |
5,698,247
-7,400,245
| -56% | -$1.44B | 0.1% | 215 |
|
|
2021
Q2 | $2.64B | Sell |
13,098,492
-3,451,384
| -21% | -$722M | 0.24% | 85 |
|
|
2021
Q1 | $3.56B | Sell |
16,549,876
-3,077,048
| -16% | -$676M | 0.36% | 50 |
|
|
2020
Q4 | $4.63B | Sell |
19,626,924
-744,000
| -4% | -$171M | 0.48% | 34 |
|
|
2020
Q3 | $5.54B | Sell |
20,370,924
-827,578
| -4% | -$228M | 0.64% | 25 |
|
|
2020
Q2 | $6.15B | Sell |
21,198,502
-425,404
| -2% | -$115M | 0.77% | 18 |
|
|
2020
Q1 | $5.15B | Sell |
21,623,906
-2,901,999
| -12% | -$666M | 0.81% | 18 |
|
|
2019
Q4 | $5.37B | Sell |
24,525,905
-1,764,208
| -7% | -$357M | 0.7% | 26 |
|
|
2019
Q3 | $4.45B | Buy |
26,290,113
+1,404,232
| +6% | +$248M | 0.63% | 29 |
|
|
2019
Q2 | $4.56B | Sell |
24,885,881
-1,260,763
| -5% | -$220M | 0.64% | 27 |
|
|
2019
Q1 | $4.81B | Buy |
26,146,644
+397,233
| +2% | +$73.4M | 0.71% | 21 |
|
|
2018
Q4 | $4.27B | Buy |
25,749,411
+682,806
| +3% | +$118M | 0.72% | 22 |
|
|
2018
Q3 | $4.83B | Sell |
25,066,605
-577,057
| -2% | -$103M | 0.7% | 19 |
|
|
2018
Q2 | $4.36B | Sell |
25,643,662
-1,925,016
| -7% | -$298M | 0.67% | 24 |
|
|
2018
Q1 | $4.49B | Sell |
27,568,678
-770,181
| -3% | -$126M | 0.71% | 19 |
|
|
2017
Q4 | $4.25B | Buy |
28,338,859
+1,860,145
| +7% | +$275M | 0.69% | 19 |
|
|
2017
Q3 | $4.03B | Buy |
26,478,714
+1,895,502
| +8% | +$285M | 0.69% | 20 |
|
|
2017
Q2 | $3.17B | Buy |
24,583,212
+1,604,569
| +7% | +$193M | 0.57% | 28 |
|
|
2017
Q1 | $2.51B | Buy |
22,978,643
+1,118,318
| +5% | +$98.5M | 0.47% | 40 |
|
|
2016
Q4 | $1.61B | Sell |
21,860,325
-1,623,063
| -7% | -$132M | 0.32% | 75 |
|
|
2016
Q3 | $2.05B | Buy |
23,483,388
+235,525
| +1% | +$22.3M | 0.41% | 53 |
|
|
2016
Q2 | $2B | Sell |
23,247,863
-1,760,630
| -7% | -$152M | 0.42% | 47 |
|
|
2016
Q1 | $1.99B | Buy |
25,008,493
+6,185,022
| +33% | +$559M | 0.42% | 45 |
|
|
2015
Q4 | $2.37B | Buy |
18,823,471
+3,832,331
| +26% | +$463M | 0.5% | 40 |
|
|
2015
Q3 | $1.56B | Buy |
14,991,140
+1,548,208
| +12% | +$199M | 0.35% | 69 |
|
|
2015
Q2 | $1.66B | Sell |
13,442,932
-73,956
| -0.5% | -$9.32M | 0.34% | 68 |
|
|
2015
Q1 | $1.59B | Buy |
13,516,888
+226,285
| +2% | +$27.1M | 0.33% | 71 |
|
|
2014
Q4 | $1.58B | Sell |
13,290,603
-900,159
| -6% | -$101M | 0.34% | 68 |
|
|
2014
Q3 | $1.59B | Buy |
14,190,762
+323,978
| +2% | +$30.8M | 0.35% | 64 |
|
|
2014
Q2 | $1.31B | Buy |
13,866,784
+2,041,774
| +17% | +$143M | 0.28% | 88 |
|
|
2014
Q1 | $836M | Buy |
11,825,010
+2,465,595
| +26% | +$195M | 0.19% | 139 |
|
|
2013
Q4 | $695M | Buy |
9,359,415
+2,458,995
| +36% | +$171M | 0.16% | 161 |
|
|
2013
Q3 | $523M | Buy |
6,900,420
+316,258
| +5% | +$25.2M | 0.13% | 201 |
|
|
2013
Q2 | $526M | Buy |
+6,584,162
| New | +$485M | 0.14% | 188 |
|
Other funds holding VRTX
VCM
VPM
T. Rowe Price Associates's VRTX Position: Q1 2026 in Review
T. Rowe Price Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 23% in Q1 2026, selling an estimated $242M and leaving 1,760,122 shares worth $786M. The position accounts for 0.09% of the portfolio, ranked #182.
T. Rowe Price Associates first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.15B in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- T. Rowe Price Associates held 1,760,122 shares of Vertex Pharmaceuticals worth $786M as of Q1 2026.
- T. Rowe Price Associates sold 518,836 Vertex Pharmaceuticals shares in Q1 2026, an estimated $242M.
- Vertex Pharmaceuticals made up 0.09% of T. Rowe Price Associates's portfolio in Q1 2026, its #182 holding.
- T. Rowe Price Associates first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's Vertex Pharmaceuticals position peaked at $6.15B in Q2 2020.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.